Circulating tumour cells (CTC) count and prostate-specific antigen (PSA) response measures in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (Doc)

Article2021

Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients

Rebeca Lozano, David Lorente, Isabel M. Aragón, Nuria Romero-Laorden, Paz Nombela, Joaquı́n Mateo, Alison Reid, Ylenia Cendón, Diletta Bianchini, Casilda Llácer, Shahneen Sandhu, Adam Sharp, Pasquale Rescigno, Teresa Garcés, M.I. Pacheco, Penelope Flohr, Christophe Massard, Pedro P. López‐Casas, Elena Castro, Johann S. de Bono, David Olmos

Article2017

Exploratory study of CK-M30 and pHH3 expression in Circulating Tumor Cells (CTCs) as biomarkers of docetaxel (DOC) efficacy in metastatic castration resistant prostate cancer (mCRPC)

P. Nombela Blanco, R. Lozano Mejorada, D. Lorente Estellés, Alison Reid, Nuria Romero-Laorden, Gerhardt Attard, Y. Cendón Flórez, Joaquı́n Mateo, Shahneen Sandhu, Christophe Massard, A. Montesa, Penny Flohr, M.I. Sáez, M.I. Pacheco, E. Castro Marcos, Johann S. de Bono, David Olmos

Article2012

Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).

Diletta Bianchini, Shahneen Sandhu, Amy Mulick, Andrea Zivi, Janusz Mezynski, Deborah Mukherji, Carmel Pezaro, Alison Helen Reid, Nikhil Babu Oommen, David Olmos, Aurelius Omlin, Ajit Sarvadikar, Emilda Thompson, Joanne Hunt, Elizabeth Sheridan, Gerhardt Attard, Johann S. de Bono

Article2012

Improved Survival in Patients with Metastatic Castration Resistant Prostate Cancer (MCRPC) Treated on Clinical Trials

Carmel Pezaro, Aurelius Omlin, Deborah Mukherji, Shahneen Sandhu, Diletta Bianchini, Amy Mulick, Gal Maier, David Olmos, Gerhardt Attard, Johann S. de Bono

Article2023

1825P Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)

David L. Goode, Shivakumar Keerthikumar, Santosh Gupta, Anthony M. Joshua, Louise Emmett, Megan Crumbaker, Tori Singer, Ernest W.N. Lam, L. Fernández, E. Jiménez, Dou Zhang, Yvonne G. Lin, Richard Wenstrup, Anupama Pasam, Rodney J. Hicks, Grace Kong, Anis Hamid, Shahneen Sandhu

Discussion(0)

Related publications